Home › Ventricular Premature Complexes › NCT03218137
Use of Adenosine to Determine the Electrophysiological Mechanism of Premature Ventricular Contractions
Who can join
Ages 18 to 70 · All sexes · Healthy volunteers welcome
Full eligibility criteria
Inclusion Criteria: * Diagnosis of premature ventricular contractions (PVCs) * Scheduled to undergo an electrophysiology study with the intention of performing cardiac ablation for the treatment of PVCs * Male or female between the ages of 18 and 70 years * Capable of giving informed consent Exclusion Criteria: * Any structural heart disease * Coronary artery disease (≥ 70% stenosis) * Current treatment with anti-arrhythmic drugs * Pregnant * Asthma (if administering adenosine)
About the study
Unblinded, controlled, non-randomized, mechanistic study to determine whether physiological mechanisms underlying PVC are sensitive to adenosine. One hundred subjects undergoing clinically-indicated, standard-of-care cardiac electrophysiology study (EPS) procedure for PVCs will receive adenosine and/or verapamil to learn if their arrhythmias are inducible similarly to sustained ventricular tachycardia.
What is being tested
- Adenosine (drug)
Sponsor: Weill Medical College of Cornell University · Participants: 100 · Started: Feb 13, 2017
Contact the study team
- James E Ip, M.D · Phone: 212 746 2158
- Dolores T Reynolds, BSN · Phone: 212 746 4617
Official record on ClinicalTrials.gov — NCT03218137
Locations in the U.S.
| New York | Weill Cornell Medicine, New York |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.